Skip to content

Oral Rehydration Solution in Healthy Adults

Effects of Oral Rehydration Solution on Dehydration Recovery in Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06130475
Enrollment
26
Registered
2023-11-14
Start date
2024-03-15
Completion date
2024-12-16
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dehydration

Brief summary

This is a prospective, randomized, controlled, blinded, crossover study to evaluate the effects of an oral hydration solution.

Interventions

Participants will be administered the ORS during one of the study visits

OTHERWater

Participants will be administered water during one of the study visits

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant is 18 to 40 years of age. * Participant has a body mass index (BMI) ≥ 18 and ≤ 30 kg/m2 * Participant reports having a moderate to heavy sweat rate when physically exerted or in extreme heat * Participant is male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. * Participant has a systolic blood pressure \<130 mm Hg and a diastolic blood pressure \< 90 mm Hg without the use of anti-hypertensive medications. * Participant reports no predisposing cardiovascular conditions. * If female, participant has a regular menstrual cycle * Participant is willing to consume grape-flavored beverages during the study. * If participant is on chronic medication the dosage must be constant for at least 2 months prior to enrollment and able to maintain medication, type and dose throughout duration of study * Participant is weight-stable for the two months prior to screening visit * Participant has voluntarily signed and dated an informed consent form (ICF), approved by an IRB, and provided applicable privacy regulation authorization prior to any participation in the study * Participant has no known intolerance or allergy to ingredients in study products * Participant is willing to refrain from using saunas or hot tubs for the duration of the study * Participant is able and willing to follow study procedures and complete any forms or assessments needed during the study

Exclusion criteria

* Participant is a current or recent (the past 8 weeks) participant in a weight-conscious sport such as but not limited to wrestling, powerlifting, boxing, rowing, gymnastics or any martial arts, with participation defined as ≥ 3x weekly training * Participant is currently, and for the past 4 weeks or longer: running \>40 miles per week on average, cycling \>80 miles per week on average or swimming \>20,000 yards per week on average * Participant is participating in another study that has not been approved as a concomitant study * Participant has used a sauna in the past 4 weeks * Participant uses any form of tobacco or nicotine, or other controlled substance not prescribed by a physician * Participant has previous history with heat illness or injury that resulted in a visit to a medical center in the past 12 months * Participant has an eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures * Participant is currently taking or has taken antibiotics within 6 weeks of enrollment * Participant is currently taking or has taken a diuretic within 1 week of enrollment * Participant has been diagnosed with the following: * Acute or chronic infections including but not restricted to respiratory infections, diarrhea, Hepatitis B or C, HIV infection or tuberculosis * Severe gastrointestinal disorders such as celiac disease, short bowel syndrome, pancreatic insufficiency, or cystic fibrosis * Metabolic \[including diabetes\], renal, hepatic, or respiratory disease * Active malignancy * Polycystic ovary disease * Any other clinically significant medical condition, which in the investigator's opinion, makes him or her unsuitable for inclusion in the study

Design outcomes

Primary

MeasureTime frameDescription
Plasma VolumeThrough Study completion, an average of 2 weeksCalculated Change in Plasma Volume

Secondary

MeasureTime frameDescription
Hydration Status UrineThrough Study completion, an average of 2 weeksChange in Urine Osmolality
Blood Biomarker - Plasma OsmolalityThrough Study completion, an average of 2 weeksChange in Plasma Osmolality
Body MassThrough Study completion, an average of 2 weeksBody Mass Loss
Blood Biomarker - Glucose ConcentrationThrough Study completion, an average of 2 weeksChange in Plasma Glucose Concentration
Body TemperatureThrough Study completion, an average of 2 weeksChange in degrees Celsius
Blood Biomarker - Plasma Electrolyte ConcentrationThrough Study completion, an average of 2 weeksChange in Electrolyte Concentration

Other

MeasureTime frameDescription
Blood PressureThrough Study completion, an average of 2 weeksChange in Blood Pressure as measured systolic/diastolic mm Hg
Thirst Sensation ScaleThrough Study completion, an average of 2 weeksParticipant completed categorical scale based on not thirsty at all to very, very thirsty
Body FatThrough Study completion, an average of 2 weeksChange in Body Fat Composition as measured by Bioimpedance Analyzer
PalatabilityThrough Study completion, an average of 2 weeks3 participant completed palatability questions on Likert scale scored from 1 (Dislike/Not at all) to 9 (Extremely)
Adverse EventsThrough Study completion, an average of 2 weeksParticipant Experienced Adverse Events
Gagge Thermal ScaleThrough Study completion, an average of 2 weeksChange in participant reported comfort (scored 1 Comfortable to 4 Very Uncomfortable) and sensation (scored 1 Cold to 7 Hot)
Body WaterThrough Study completion, an average of 2 weeksChange in Body Water as measured by Bioimpedance Analyzer
Reaction TimeThrough Study completion, an average of 2 weeksChange in Reaction Time
Handgrip StrengthThrough Study completion, an average of 2 weeksChange in Handgrip Strength measured via Hand Dynamometer
Urine VolumeThrough Study completion, an average of 2 weeksUrine Collection
Hydration Status SalivaThrough Study completion, an average of 2 weeksChange in Saliva Osmolality
Heart RateThrough Study completion, an average of 2 weeksChange in Heart Rate as measured beats per minute

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026